… -acting beta agonist (salbutamol) and a short-acting muscarinic antagonist (ipratropium
bromide), … In brief, the progression of COPD was characterized through a set of risk equations to …

… 4,66%, and anticholinergics were Salbutamol with ipratropium 54% and salbutamol with …
combinations used commonly are salbutamol with ipratropium bromide and salbutamol with …

… study evaluated ipratropium bromide/albuterol delivered by … For example, a multicenter,
retrospective analysis of medical … β 2 -agonist fixed-dose combination identified that the inhaler …

… with LAMA in combination with ICS alone or ICS plus LABA. … are classified as short acting
(eg, ipratropium; DOA, 4-8 hours) … 400 mL following administration of salbutamol 400 μg. A post …

… All included studies in this review compared triple therapy against ICS plus a LABA as
maintenance with short-acting β-agonist as reliever. Although ICS–rapid-onset LABA as single …

… like salbutamol, levosalbutamol, levosalbutamol plus ipratropium … combinations was the
highest (46%), followed by three drug … Prescribing patterns and pharmacoeconomic analysis of …

… Assessment Measure (PRAM) score of 5 or greater (on a 12-point scale) after a 1-hour treatment
with an oral corticosteroid and 3 inhaled albuterol and ipratropium … outcome set at 0.01 …

… evaluated peer-reviewed CE and appropriate-use evaluations of budesonide/formoterol
combination … normal, use of ≥12 actuations of albuterol per day on ≥3 days within any period …

… Rational health policy is based on pharmacoeconomic analyses. … that SABA as well as the
combination of SABA and SAMA used in … Salbutamol and ipratropium by inhaler is superior to …

… , albuterol, sodium phosphate enema, ipratropium, and … A pharmacoeconomic analysis
of 244 of the interventions … Our study showed a substantial combined cost savings and cost …